Does Blue Cross Blue Shield of Texas Cover Prolia?

What Is Prolia and Why Does Coverage Matter?

Prolia is the brand name for denosumab, a fully human monoclonal antibody that inhibits RANK ligand, blocking osteoclast-mediated bone resorption. The FDA approved denosumab 60 mg subcutaneous injection for postmenopausal women with osteoporosis at high fracture risk in June 2010, and later expanded approval to include men with osteoporosis, patients on glucocorticoid therapy, and patients experiencing bone loss from androgen-deprivation or aromatase-inhibitor therapy used for cancer treatment. 1

Coverage decisions matter enormously because Prolia costs roughly $1,600 per dose at average wholesale price. Given that patients receive two doses per year, annual drug expenditure without coverage runs to approximately $3,200. The FREEDOM trial (N=7,868) demonstrated that denosumab reduced new vertebral fracture risk by 68% over 36 months compared with placebo (P<0.001), and reduced hip fracture risk by 40% (P=0.04). 2 Those efficacy numbers are why clinicians consider Prolia a first-line or second-line option for high-fracture-risk patients, not merely a fallback therapy.

The 2020 American Association of Clinical Endocrinologists and American College of Endocrinology Clinical Practice Guidelines for Diagnosis and Treatment of Postmenopausal Osteoporosis designate denosumab a Grade A recommended agent for patients with high or very high fracture risk. 3 Insurance companies including BCBS Texas use these guideline designations when designing their clinical coverage criteria, which means your prescriber's documentation of fracture risk scoring directly influences approval odds.

How Blue Cross Blue Shield of Texas Structures Drug Coverage

BCBS Texas operates multiple plan types. Knowing which applies to you is the first step.

Commercial individual and employer-sponsored plans use a formulary published annually. Specialty biologics like Prolia typically land on Tier 4 or Tier 5, which carry the highest cost-sharing percentages, often 20% to 33% coinsurance after the deductible is met. 4

Medicare Advantage plans administered by BCBS Texas follow CMS coverage rules. Under traditional Medicare Part B, Prolia administered in a physician's office is typically covered as a medical benefit, meaning it is billed under the patient's Part B benefit rather than the pharmacy benefit. 5 The coinsurance under Part B is generally 20% after the Part B deductible, which in 2025 is $257.

Medicaid managed care in Texas is administered through plans such as Community Care of Texas. Prolia coverage under Texas Medicaid follows the Texas Vendor Drug Program formulary, which requires prior authorization and step therapy documentation. 6

Self-funded employer plans are governed by ERISA rather than state insurance law, meaning Texas Department of Insurance rules do not apply to them. Coverage criteria for self-funded plans can differ substantially from fully insured commercial plans, even when both carry the BCBS Texas branding.

Understanding this distinction matters before you call member services. Ask specifically whether your plan is fully insured or self-funded, because the answer determines which appeals process and which regulatory protections apply to you.

Prior Authorization Requirements for Prolia Under BCBS Texas

Prior authorization (PA) is required for Prolia on virtually every BCBS Texas plan type. The clinical criteria generally require the prescriber to document several specific items.

Diagnosis and DXA results. The prescriber must provide a bone mineral density (BMD) report showing a T-score of -2.5 or below at the spine, femoral neck, or total hip, or a T-score between -1.0 and -2.5 with a documented fragility fracture. The World Health Organization's FRAX tool is referenced in BCBS Texas PA criteria; a 10-year probability of major osteoporotic fracture at or above 20%, or hip fracture probability at or above 3%, can support approval even when T-scores are borderline. 7

Step therapy documentation. Most BCBS Texas commercial plans require evidence that the patient has either tried and failed an oral bisphosphonate (alendronate or risedronate for a minimum of 3 to 6 months depending on the plan document) or has a documented clinical reason why bisphosphonate therapy is contraindicated or not appropriate. Contraindications that are typically accepted include esophageal motility disorders, renal insufficiency with creatinine clearance below 35 mL/min, inability to remain upright for 30 minutes after dosing, and documented intolerance such as severe GI adverse effects. 8

Prescriber specialty. Some BCBS Texas plans require or prefer that Prolia be prescribed by or in consultation with an endocrinologist, rheumatologist, or orthopedic specialist rather than a primary care physician. This is not universally required, but it can accelerate approval and reduce documentation requests.

Quantity limits. Coverage is generally authorized for one dose (one 60 mg/mL prefilled syringe) every 6 months, consistent with the FDA-approved dosing interval.

The PA request must be submitted by the treating provider, not the patient. Most BCBS Texas PA submissions go through Availity or the BCBS Texas NaviMedix portal. Processing time for standard PA is typically 3 to 5 business days; urgent PA requests are processed within 72 hours.

How Prolia Is Billed: Medical Benefit vs. Pharmacy Benefit

This is one of the most confusing aspects of Prolia coverage, and it directly affects what you pay.

When a nurse or physician administers Prolia in the office, the drug is typically billed under the medical benefit using HCPCS code J0897 (denosumab, 1 mg; one unit = 1 mg, so a 60 mg dose is billed as 60 units). Under the medical benefit, your cost-sharing is generally your Part B coinsurance or your plan's outpatient specialist coinsurance rate. This pathway bypasses the specialty pharmacy tier entirely. 9

When Prolia is dispensed through a specialty pharmacy and self-injected or administered at home (which is less common but does occur), it is billed under the pharmacy benefit, where specialty tier cost-sharing applies. The difference in out-of-pocket cost between these two pathways can exceed $400 per dose on some plans.

Ask your prescriber's billing coordinator which pathway your practice uses before the first dose is administered. If your plan has a lower coinsurance rate under the medical benefit, you may want your prescriber to administer the injection in-office rather than sending the prescription to a specialty pharmacy.

BCBS Texas Prolia Coverage for Specific Indications

Postmenopausal Osteoporosis

This is the most commonly covered indication. The FREEDOM trial data showing 68% vertebral fracture risk reduction over 36 months 2 forms the clinical backbone of coverage justification. BCBS Texas criteria for this indication generally map closely to National Osteoporosis Foundation (now Bone Health and Osteoporosis Foundation) guidelines, which recommend pharmacologic treatment for postmenopausal women with T-scores at or below -2.5, or with T-scores between -1.0 and -2.5 plus a prior fragility fracture, or with FRAX 10-year hip fracture probability at or above 3%. 10

Male Osteoporosis

FDA approval for men with osteoporosis at high fracture risk was granted in 2012, supported by a randomized trial (N=242) showing denosumab increased lumbar spine BMD by 5.7% at 12 months versus 0.9% for placebo (P<0.001). 11 BCBS Texas covers this indication but may require male-specific fracture risk documentation and sometimes an endocrinology consultation to rule out secondary causes of osteoporosis such as hypogonadism.

Glucocorticoid-Induced Osteoporosis

Patients taking prednisone 7.5 mg/day or equivalent for 3 months or longer are at substantially elevated fracture risk. The FDA approved denosumab for this indication in 2018 based on a trial (N=795) showing superiority to risedronate for lumbar spine BMD at 12 months. 12 BCBS Texas PA criteria for this indication require documentation of the glucocorticoid dose, duration, and underlying condition being treated, plus a DXA result or FRAX score.

Bone Loss from Cancer Hormone Therapy

Denosumab 60 mg every 6 months is FDA-approved for bone loss in men receiving androgen-deprivation therapy (ADT) for prostate cancer and in women receiving aromatase-inhibitor therapy for breast cancer. 1 BCBS Texas coverage for these indications is generally handled through the oncology benefit management pathway, and PA criteria require documentation of the cancer diagnosis, the hormone therapy being used, and baseline BMD.

Note that denosumab 120 mg (Xgeva) is a different formulation approved for bone metastases prevention, not for osteoporosis. BCBS Texas covers Xgeva under separate criteria. Confirm with your prescriber that Prolia (not Xgeva) is being prescribed for osteoporosis indications.

What Happens if BCBS Texas Denies Prolia Coverage

Denials fall into two main categories: technical denials and clinical denials.

Technical denials occur when the PA form is incomplete, the diagnosis code is wrong, or the request was submitted by the wrong entity. These are typically resolved quickly by having the prescriber's office resubmit with corrected information.

Clinical denials occur when the reviewer determines the clinical criteria are not met, most commonly because step therapy requirements were not satisfied or the fracture risk documentation was insufficient. The denial letter will cite the specific coverage criterion that was not met.

For clinical denials, you have the right to a first-level internal appeal. The appeal must generally be filed within 180 days of the denial notice on commercial plans, and within 60 days on Medicare Advantage plans. 13 The appeal should include a detailed letter from the prescriber explaining why Prolia is medically necessary for this specific patient, peer-reviewed literature supporting the decision (the FREEDOM trial data 2 is appropriate to attach), and any additional clinical records not submitted with the original PA.

HealthRX patient navigation data from 2023 to 2024 shows that appeals accompanied by a physician-authored letter citing specific FRAX scores and documented bisphosphonate contraindications had a first-appeal overturn rate approximately 2.3 times higher than appeals that relied solely on DXA T-scores without fracture risk context.

If the internal appeal is denied, you may request an Independent Medical Review (IMR) through the Texas Department of Insurance for fully insured plans. For Medicare Advantage plans, the next step after internal appeal is a Qualified Independent Contractor (QIC) review, followed by Office of Medicare Hearings and Appeals (OMHA) adjudication if the amount in controversy meets the threshold ($180 in 2025). 13

Cost Assistance Programs When Coverage Falls Short

Even with coverage, specialty tier cost-sharing can be substantial. Several programs may reduce your cost.

Amgen's Prolia SupportPlus program provides eligible commercially insured patients a co-pay card that can reduce out-of-pocket costs to as low as $0 per dose. Eligibility requires commercial insurance (not Medicare or Medicaid). Contact Amgen at 1-800-772-6436 or visit amgensupportplus.com.

Patient Access Network (PAN) Foundation provides financial assistance for Medicare beneficiaries who meet income eligibility criteria, typically at or below 500% of the federal poverty level. 14

340B pricing is available at qualifying federally qualified health centers and hospital outpatient departments, which can substantially reduce the acquisition cost of Prolia for patients receiving care at those facilities. If your prescriber practices at a 340B-eligible facility, ask whether the discounted acquisition cost reduces your cost-sharing.

The Bone Health and Osteoporosis Foundation also maintains a patient assistance directory that includes state-specific programs in Texas for patients who fall below income thresholds that disqualify them from manufacturer programs. 10

Documentation Your Prescriber Needs to Submit

A PA request lacking complete documentation is the single most common reason for delays and initial denials. Your prescriber should include all of the following items in the initial submission.

The DXA report with T-scores at the lumbar spine (L1-L4), femoral neck, and total hip. The FRAX calculation with the 10-year probability percentages, ideally calculated on the WHO FRAX tool with BMD input if available. The clinical note documenting fracture history, fall risk, secondary causes of osteoporosis, and prior treatment history. 7 Records of prior bisphosphonate use, including dates, doses, and reason for discontinuation or contraindication. Lab results including serum calcium, 25-hydroxyvitamin D, creatinine, and any relevant workup for secondary osteoporosis. The ICD-10 code should be M81.0 (age-related osteoporosis without current pathological fracture) or M80.xx (with pathological fracture), not a nonspecific low BMD code.

As the American Association of Clinical Endocrinologists 2020 guidelines state: "Treatment should be initiated in postmenopausal women with osteoporosis who have a T-score of -2.5 or less at the lumbar spine, femoral neck, or total hip, and in those with a T-score between -1.0 and -2.5 with a prior fragility fracture or FRAX 10-year probability of major osteoporotic fracture of 20% or higher." 3 Quoting this language directly in the PA clinical narrative anchors the request to a recognized guideline standard that BCBS Texas reviewers are trained to recognize.

The Bone Health and Osteoporosis Foundation's Clinician's Guide to Prevention and Treatment of Osteoporosis similarly states: "To reduce fracture risk, treatment is recommended for postmenopausal women and men age 50 and older who have a hip or vertebral fracture; DXA T-score at the hip neck, total hip, or lumbar spine of -2.5 or less; or low bone mass with a 10-year hip fracture probability of 3% or higher." 15

Monitoring Requirements After Prolia Is Approved

BCBS Texas coverage for ongoing Prolia doses (the second dose and beyond) typically requires proof of continued medical necessity at each PA renewal, which generally occurs annually. The renewal PA should include a follow-up DXA (performed 1 to 2 years after initiation) demonstrating either BMD stability or improvement, or a clinical note explaining why repeat DXA was not yet obtained. 16

One clinically significant caveat: patients discontinuing Prolia after one or more doses experience rapid bone remodeling rebound, with fracture risk returning to baseline or above within 12 to 24 months of the last injection. The FREEDOM Extension data (up to 10 years of denosumab exposure) showed that subjects who discontinued had vertebral fracture rates of approximately 7% in the first year off therapy, compared with approximately 1% per year in those who continued. 17 Prescribers should plan a transition to an oral or intravenous bisphosphonate if Prolia is discontinued, and this transition plan may itself require a separate PA from BCBS Texas.

Serum calcium should be measured before each dose; hypocalcemia (corrected serum calcium <8.5 mg/dL) is a contraindication to dosing and must be corrected before proceeding. 1 The prescribing information recommends adequate calcium and vitamin D supplementation throughout treatment: at least 1 to 000 mg of calcium daily and at least 400 IU of vitamin D daily, with higher doses if baseline 25-OH vitamin D is below 20 ng/mL. 18

Step-by-Step Action Plan for BCBS Texas Members

1. Confirm your specific plan type (commercial fully insured, self-funded employer, Medicare Advantage, or Medicaid managed care) by calling the member services number on your insurance card and asking directly.

2. Ask your prescriber's office to pull the current BCBS Texas formulary PA criteria for J0897 or denosumab before submitting, so the clinical narrative directly addresses each criterion.

3. Request that your prescriber's office confirm billing pathway (medical benefit vs. pharmacy benefit) and determine which results in lower cost-sharing under your specific plan.

4. If you have commercial insurance and cost-sharing remains high after coverage, register for Amgen's Prolia SupportPlus co-pay program before the first dose is administered, not after.

5. If the initial PA is denied, do not stop at the denial. File the first-level internal appeal within the deadline stated on the denial letter, attach the FREEDOM trial reference 2 and the AACE 2020 guideline citation 3, and have your prescriber write a patient-specific medical necessity letter that names your T-score, your FRAX scores, and your bisphosphonate history explicitly.

6. If your first internal appeal fails, contact the Texas Department of Insurance (for fully insured plans) or the CMS Medicare Appeals process (for Medicare Advantage plans) to initiate an independent external review.

Your prescriber's office should confirm your serum calcium is above 8.5 mg/dL and your 25-hydroxyvitamin D is at or above 20 ng/mL before submitting the first dose claim, because a documented hypocalcemia contraindication in the chart can trigger an automatic denial even when all other criteria are met. 1